BFLY trades 39.1% above Wall Street's consensus target of $5.42.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BFLY achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Butterfly Network, Inc. (BFLY) has a Wall Street consensus price target of $5.42, based on estimates from 7 covering analysts. With the stock currently trading at $8.90, this represents a potential downside of -39.1%. The company has a market capitalization of $2.33B.
Analyst price targets range from a low of $5.25 to a high of $5.50, representing a 5% spread in expectations. The median target of $5.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BFLY trades at a trailing P/E of -28.7x. Analysts expect EPS to grow +57.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SONOSonos, Inc. | $1.8B | $14.68 | $19.50 | +32.8% | Buy | 37.6x | 9 |
INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
AEYEAudioEye, Inc. | $79M | $6.31 | — | — | — | — | — |
EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
PRCTPROCEPT BioRobotics Corporation | $1.2B | $21.72 | $32.00 | +47.3% | Buy | — | 15 |
EWEdwards Lifesciences Corporation | $50.4B | $87.36 | $96.55 | +10.5% | Buy | 29.0x | 48 |
ISRGIntuitive Surgical, Inc. | $144.5B | $406.78 | $597.78 | +47.0% | Buy | 38.9x | 55 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
ATECAlphatec Holdings, Inc. | $1.3B | $8.81 | $18.00 | +104.3% | Buy | 27.5x | 18 |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
Quick answers to the most common questions about buying BFLY stock.
BFLY's consensus price target is $5.42, -39.1% below the current price of $8.9. The 7 analysts tracking BFLY see downside risk at present valuations.
BFLY has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $5.42 implies -39.1% downside from current levels.
BFLY's current price is $8.9 with a consensus target of $5.42 (-39.1% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $5.5 for BFLY, while the most conservative target is $5.25. The consensus of $5.42 represents the median expectation. These targets typically reflect 12-month expectations.
BFLY is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BFLY stock forecast based on 7 Wall Street analysts shows a consensus price target of $5.42, with estimates ranging from $5.25 (bear case) to $5.5 (bull case). The median consensus rating is "Buy".
Analysts are cautious on BFLY, with 0 Sell ratings and a price target of $5.42 (-39.1% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BFLY analyst price targets range from $5.25 to $5.5, a 5% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.42 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.